Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

Rheumatology

Volumn 49, Issue 2, 2010, Pages 289-294

  Scarpato, Salvatore ^a   Antivalle, Marco ^b   Favalli, Ennio G ^c   Nacci, Francesca ^d   Frigelli, Sabrina ^e   Bartoli, Francesca ^d   Bazzichi, Laura ^f   Minisola, Giovanni ^g   Cerinic, Marco Matucci ^d  

^a Rheumatology Unit   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c G Pini Orthopaedic Institute   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e Rheumatology Unit   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Anti TNF therapy; Decision making; Patient empowerment; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOCTOR PATIENT RELATION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG UTILIZATION; FEMALE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HOME CARE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; REASSURANCE; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHOICE BEHAVIOR; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; ITALY; MALE; MIDDLE AGED; PATIENT PREFERENCE; SELF ADMINISTRATION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77950431787     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep354     Document Type: Article

References (22)

1. Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology 2004;43:1034-8.
2. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34(5 Suppl. 1):7-11.
3. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl. 2):ii13-6.
4. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-248.
5. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
6. Kennedy T, McCabe C, Struthers G et al. BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology 2005;44:553-6.
7. Kirwan JR, Hewlett SE, Heiberg T et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. J Rheumatol 2005;32:2250-6.
8. Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? Qual Health Care 2001;10(Suppl 1):i39-43.
9. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004;63:1372-8.
10. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology 2006;45:1575-6.
11. Charles C, Gafni G, Whelan T. Decision making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med 1999;49:651-61.
12. Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004;6(Suppl. 2):S19-23.
13. Neame R, Hammond A, Deighton C. Need for information and for involvement in decision making among patients with rheumatoid arthritis: a questionnaire survey. Arthritis Rheum 2005;53:249-255.
14. Kjeken I, Dagfinrud H, Mowinckel P, Uhlig T, Kvien TK, Finset A. Rheumatology care: involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 2006;55:394-401.
15. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9(6 Suppl.):S136-43.
16. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
17. Fransen J, Langenegger B, Michel A, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology 2000;39:321-7.
18. Saltman DC, Sayer GP, O'Dea NA. Dosing frequencies in general practice-whose decision and why? Aust Fam Physician 2006;35:915-9.
19. Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis Rheum 2006;55:729-35.
20. Kittner JM, Grimbacher B, Wulff W, Jager B, Schmidt RE. Patients' attitude to SC immunoglobulin substitution as home therapy. J Clin Immunol 2006;26:400-5.
21. Bertinotti L, Nacci F, Matucci Cerinic M. The measurement of outcome and the rheumatoid arthritis core set to lift the prejudice of the 'thaumaturgus liché'. Rheumatology 2006;45:1055-7.
22. Ishikawa H, Hashimoto H, Yano E. Patient's preferences for decision making and the feeling of being understood in the medical encounter among patients with rheumatoid arthritis. Arthritis Rheum 2006;55:878-83.